lence of albuminuria among First Nations people, suggesting the potential association between albuminuria and risk of kidney failure. 8, 9 We sought to measure the presence and severity of albuminuria and estimate the risk of progression to kidney failure for First Nations people compared with non-First Nations people using a community-based cohort.
Methods

Study design and population
We performed a population-based cohort study of all adults 18 years of age or older in Alberta. 10 We included adults for whom at least 1 outpatient serum creatinine measurement had been done for clinical care between May 1, 2002, and Mar. 31, 2008 . We excluded patients who received dialysis or kidney transplant before cohort entry, or who had an estimated GFR of less than 15 mL/min per 1.73 m 2 . This study was approved by the University of Calgary Conjoint Health Research Ethics Board and the University of Alberta Research Ethics Office.
Classification of ethnicity
First Nations ethnicity was determined from a First Nations status indicator variable in the Alberta Health Registry file, which identifies people registered with Aboriginal Affairs and Northern Development Canada under the Indian Act. A person with a First Nations identifier at any point in time from Apr. 1, 1994 (the earliest date of the use of the First Nations identifier in the data) to Mar. 31, 2008, was classified as First Nations; all other people were classified as nonFirst Nations. 11 First Nations people in Alberta not registered under the Indian Act (that is, without a First Nations status indicator in their registry files) were classified as non-First Nations, and they account for less than 30% of Alberta's First Nations population.
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Assessment of kidney function and albuminuria Glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation. 13 The index value was categorized as follows: 90.0 or more, 60.0-89.9, 45.0-59.9, 30.0-44.9 and 15.0-29.9 mL/min per 1.73 m 2 . Albuminuria was measured by urine dipstick on spot urine samples. For participants with multiple measurements of albuminuria, the median value was calculated from all measurements available for the 6 months before and 6 months after the index date (i.e., the date of the index estimated GFR). As in previous studies, 14, 15 albuminuria was categorized as normal (negative, median value of 0), mild (trace or +1, median value of 1 or 2), heavy (+2 or higher, median value of 3 or more) and not measured (for patients with no urine dipstick measurement during the 1-yr observation period). We chose to use albuminuria measured by urine dipstick rather than urine albumin to creatinine ratio, because urine dipstick measurements are available for more people. Furthermore, our previous work has shown that albuminuria is an important determinant of clinical outcomes, including progression to kidney failure, whether assessed by urine dipstick or urine albumin to creatinine ratio, 14 supporting the validity of this measure. 16 Data on visits to physicians were obtained from the physicians' billing claims database. Specialist care was defined as having at least 1 outpatient visit to a nephrologist or general internist in the year before the index date. Diabetes and hypertension were identified from hospital discharge records and physicians' billing claims using validated algorithms. 17, 18 Comorbid conditions were defined from physician claims and hospital admissions data using validated coding algorithms and the clinical modification of the International Classification of Diseases, 9th revision, and the International Classification of Diseases, 10th revision. 19 Health services data were captured for all residents of Alberta during the study period, regardless of movement within the province.
Measurement of sociodemographic variables and comorbidities
Outcome measure
Our primary outcome was progression to kidney failure, defined as the occurrence of one of the following events: chronic dialysis, renal transplantation or a sustained doubling of serum creatinine (i.e., levels twice as high as that of the index measurement for all subsequent measurements). This definition is often used in studies of renal outcomes. 20 Participants were followed from their index date to the occurrence of the study outcome, their death (identified from the Alberta Bureau of Vital Statistics), their emigration from Alberta or the end of the study period (Mar. 31, 2009).
Statistical analysis
Baseline characteristics were described using means, medians and interquartile ranges (IQRs) or proportions. Rates of progression to kidney failure by First Nations status, estimated GFR and albuminuria were calculated using Poisson regression, adjusting for sociodemographic variables and comorbid conditions. If the Poisson assumption that the variance equals its mean was not met, a quasi-Poisson model was used. Relative hazards of progression to kidney failure comparing First Nations versus non-First Nations participants were calculated using Cox proportional hazards models, by level of albuminuria and estimated GFR. To determine whether the relationship between First Nations status and outcome varied by albuminuria level and estimated GFR, interaction terms (First Nations and albuminuria; First Nations and estimated GFR) were used. We also included an interaction term for First Nations and diabetes to determine whether the relationship of First Nations status and progression to end-stage kidney disease varied with diabetes status. We used Schoenfeld residuals to test the proportional hazards assumptions for our variables of interest. 21 We repeated all analyses using competing risk proportional subdistribution hazards methods defined by Fine and Gray. 22 A significance level of 0.05 was used for all statistical tests. We performed all analyses using R statistical software.
Results
Participants
We identified 1 821 619 residents of Alberta 18 years of age or older for whom least 1 outpatient serum creatinine measurement had been done during the study period. Of these residents, 78% of non-First Nations and 72.5% of First Nations patients had 1 or more creatinine measurements during follow-up. We excluded 3168 patients who had received dialysis or a kidney transplant and 1627 patients with an estimated GFR of less than 15.0 mL/min per 1.73 m 2 at the start of the observation interval. Our final cohort included 1 816 824 patients, 48 669 (2.68%) of whom had First Nations ethnicity.
Overall, First Nations participants were younger and more likely to live in a rural location in the lowest income quintile (Table 1) than were non-First Nations participants. The prevalence of diabetes and other comorbid conditions was higher among First Nations people than among non-First Nations people ( Table 2) . A greater proportion of First Nations people (97.1%) had an estimated GFR higher than 60.0 mL/min per 1.73 m 2 compared with nonFirst Nations people (92.7%). First Nations people were more likely than non-First Nations people to have mild or heavy albuminuria (7.6% v. 5.2%). Most First Nations people (53.8%) had no measure of albuminuria, compared with 38.5% of non-First Nations people (Table 1) .
Primary outcome
The median length of follow-up was 4.4 years for both non-First Nations and First Nations participants (IQR 2.9 yr for non-First Nations; IQR 3.0 yr for First Nations). Chronic kidney disease progressed to kidney failure in 605 (1.24%) First Nations and 10 990 (0.62%) non-First Nations participants. Among participants with an estimated GFR of more than 90.0 mL/min per 1.73 m 2 at baseline, about 20% in both groups reached the outcome of sustained doubling of creatinine, but had an estimated GFR of more than 60.0 mL/min per 1.73 m 2 by the end of the observation period.
Adjusted rates of progression to kidney failure were consistently 2-to 3-fold higher among First Nations participants than among non-First Nations participants for all levels of estimated GFR and albuminuria (Table 3) . For example, among participants with an estimated GFR of 15.0-29.9 mL/min per 1.73 m 2 and mild albuminuria, adjusted rates of progression to kidney failure per 1000 person years were 20.57 (95% confidence interval [CI] 9.85-42.94) and 9.44 (95% CI 7.85-11.34) for First Nations and nonFirst Nations participants, respectively.
For both non-First Nations and First Nations participants, not having a measure of albuminuria was associated with rates of progression to kidney failure that were intermediate to those for normal or mild albuminuria. In addition, the lowest rates of progression to kidney failure for both groups were seen in participants with normal albuminuria, and the highest rates were seen among those with heavy albuminuria.
Likelihood of progression to kidney failure
For all levels of albuminuria and estimated GFR, the adjusted risk of progression to kidney failure was significantly greater for First Nations than for non-First Nations people (Figure 1) . The greatest risk of progression to kidney failure for First Nations people was among those with an estimated GFR of 15.0-29.9 mL/min per 1.73 m 2 , for whom risk was consistently 2-to 3-fold higher than for non-First Nations people with a similar estimated GFR. This increased risk was present regardless of the level of albuminuria, as well as among those with no measure of albuminuria. For example, compared with non-First Nations participants, the hazard ratio for kidney failure among First Nations people with an estimated GFR of 15.0-29.9 mL/min per 1.73 m 2 was 2.92 (95% CI 2.09-4.07) in the setting of normal albuminuria, and 2.53 (95% CI 1.88-3.40) in the setting of heavy albuminuria. Similarly, among First Nations participants with no albuminuria measurement, the hazard ratio of progression to kidney failure was 3.22 (95% CI 2.45-4.24).
The interactions between First Nations status and diabetes, First Nations status and albuminuria, and First Nations status and estimated GFR were not significant, suggesting that progression to kidney failure was consistently higher for First Nations than for non-First Nations participants. In analyses accounting for competing risk of death, similar patterns in risk of progression to end-stage kidney disease for First Nations and non-First Nations participants were evident. In total, 2295 (4.72%) First Nations participants and 89 357 (5.05%) non-First Nations participants died before reaching the primary outcome.
Interpretation
We found that First Nations participants had 2-to 3-fold higher rates of progression to kidney failure than non-First Nations participants, across all levels of kidney function and regardless of the presence or severity of albuminuria. Compared with non-First Nations participants, the greatest risk of progression to kidney failure for First Nations participants occurred among those with the lowest estimated GFR (15.0-29.9 mL/min per 1.73 m 2 ). These results were consistent regardless of the presence or severity of albuminuria, and after adjusting for sociodemographic characteristics, comorbidities and specialist care, as well as when death was considered as a competing risk. These results suggest that features other than those considered here contribute to the higher rates of kidney failure among First Nations people.
Our results are consistent with previous studies reporting rates of kidney failure 2-to 4-fold higher for First Nations compared with nonFirst Nations people, even among those who do not have diabetes. 4, 5, 23, 24 Similar to Dyck and colleagues, we report an age-and sex-adjusted rate of kidney failure that is 3-fold higher for First Nations than for non-First Nations people. 24 Previous studies, however, have not included an assessment of albuminuria or potential modifying effects of albuminuria on risk of progression of kidney disease in this population. This is particularly relevant, given the association between albuminuria and progression to kidney failure in other populations.
14 Despite a higher prevalence of heavy albuminuria among First Nations people, we did not find that the presence or severity of albuminuria conferred an additional risk to the development of kidney failure. Even among participants with no measure of albuminuria, risk of progression to kidney failure was similarly elevated for First Nations compared with non-First Nations participants within each category of estimated GFR. The increase in progression to kidney failure associated with an estimated GFR of 90.0 mL/min per 1.73 m 2 or higher, consistent for all albuminuria groups, is likely due to the relationship of reduced muscle mass (reflecting ill health) to kidney function and progression to kidney failure. 25 We conclude that albuminuria has no appreciable modifying effect on the association between First Nations status and progression to kidney failure. We suggest that there are unique factors relevant to First Nations people that determine progression to kidney failure, which are independent of albuminuria.
Differences in patient-or system-level factors may explain our findings. First Nations people experience lower quality of care and limited access to specialist care, and present with more severe chronic kidney disease despite having a similar probability of creatinine measurement, compared with non-First Nations people. 26, 27 Reduced access to specialist care for First Nations people with epilepsy has also been reported. 28 Not all of the participants in our study had albuminuria measurements, with nonmeasurement more common among First Nations participants. This may represent an opportunity to improve care, because measurement of albuminuria is an indicator of overall access to care for chronic kidney disease.
Limitations
We used a community-based cohort with creatinine measurements obtained for routine clinical care, which did not include people who did not use medical services. However, we have previously reported that First Nations people are as likely as non-First Nations people to obtain a measure of serum creatinine. 1 There is a potential for misclassification of albuminuria based on urine dipstick assessment, particularly when the measurement is based on a single measure. However, the percentage of participants with unmeasured proteinuria in our cohort is similar to that seen in other cohorts of patients with chronic kidney disease. 29 Because we did not have information on variables such as blood pressure control, smoking status, individual income, mobility within the province, and for First Nations participants, medication use, residual confounding is possible.
Finally, we are unable to obtain further information regarding Aboriginal people (First Nations and non-First Nations) not registered under the Indian Act.
